On June 17, 2023, Nymox Pharmaceutical Corporation terminated the employment of each of Mr. Christopher R. Riley, Chief Financial Officer. The Company has initiated a search for a Chief Financial Officer, and is in the process of hiring a general counsel to assume the role of Mr. Lanham.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.205 USD | -14.41% |
|
+38.51% | -65.25% |
1st Jan change | Capi. | |
---|---|---|
-65.25% | 22.36M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- NYMXF Stock
- News Nymox Pharmaceutical Corporation
- Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer